The pharmacokinetics of atazanavir/ritonavir 200/100 OD versus 300/100 mg OD in combination with 2 NRTIs [nucleoside reverse transcriptase inhibitors] in HIV pre-treated patients.

Trial Profile

The pharmacokinetics of atazanavir/ritonavir 200/100 OD versus 300/100 mg OD in combination with 2 NRTIs [nucleoside reverse transcriptase inhibitors] in HIV pre-treated patients.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2010

At a glance

  • Drugs Atazanavir; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jun 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 10 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top